Insider Selling: Atea Pharmaceuticals (NASDAQ:AVIR) Director Sells $35,141.60 in Stock

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR – Get Free Report) Director Bruce Polsky sold 8,720 shares of the firm’s stock in a transaction on Tuesday, November 17th. The shares were sold at an average price of $4.03, for a total transaction of $35,141.60. Following the transaction, the director directly owned 158,580 shares of the company’s stock, valued at $639,077.40. The trade was a 5.21% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Bruce Polsky also recently made the following trade(s):

  • On Thursday, November 19th, Bruce Polsky sold 8,750 shares of Atea Pharmaceuticals stock. The stock was sold at an average price of $4.03, for a total transaction of $35,262.50.
  • On Wednesday, November 18th, Bruce Polsky sold 18,252 shares of Atea Pharmaceuticals stock. The shares were sold at an average price of $3.95, for a total value of $72,095.40.
  • On Monday, November 16th, Bruce Polsky sold 14,254 shares of Atea Pharmaceuticals stock. The shares were sold at an average price of $4.27, for a total value of $60,864.58.

Atea Pharmaceuticals Stock Up 1.0%

Shares of NASDAQ:AVIR opened at $3.97 on Friday. The firm has a market cap of $318.79 million, a P/E ratio of -2.04 and a beta of 0.76. Atea Pharmaceuticals, Inc. has a 12-month low of $2.92 and a 12-month high of $6.45. The business has a fifty day simple moving average of $4.65 and a 200 day simple moving average of $4.94.

Atea Pharmaceuticals (NASDAQ:AVIR – Get Free Report) last released its quarterly earnings results on Monday, November 9th. The company reported ($0.40) EPS for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.11. As a group, equities research analysts expect that Atea Pharmaceuticals, Inc. will post -1.60 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently commented on AVIR. Morgan Stanley lifted their price objective on Atea Pharmaceuticals from $7.00 to $8.00 and gave the stock an “equal weight” rating in a research note on Monday, November 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Atea Pharmaceuticals in a research note on Thursday, October 15th. Finally, Wall Street Zen upgraded shares of Atea Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, September 12th. One analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $8.00.

Check Out Our Latest Report on AVIR

Institutional Trading of Atea Pharmaceuticals

Several large investors have recently modified their holdings of AVIR. Legal & General Group Plc bought a new stake in shares of Atea Pharmaceuticals in the 2nd quarter valued at $33,000. Spark Investment Management LLC bought a new position in Atea Pharmaceuticals during the second quarter worth $75,000. Headlands Technologies LLC bought a new position in Atea Pharmaceuticals during the second quarter worth $77,000. Engineers Gate Manager LP bought a new position in Atea Pharmaceuticals during the second quarter worth $78,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in Atea Pharmaceuticals in the second quarter worth $82,000. Institutional investors and hedge funds own 86.67% of the company’s stock.

Atea Pharmaceuticals Company Profile

(Get Free Report)

Atea Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing oral antiviral medicines for serious viral diseases. Its research centers on compounds intended to interfere with viral replication. The company’s investigational portfolio has included bemnifosbuvir, an oral antiviral candidate studied for COVID-19, as well as programs targeting other viral infections, including dengue. These medicines are investigational and are not established marketed treatments.

Recommended Stories

Receive News & Ratings for Atea Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atea Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.